Skip to main content

Table 2 Features of the patients before the second [68 Ga]Ga-PSMA-11 PET/CT images

From: Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT

Feature    Total
Castration resistance Sensitive 20 (40%) 50 (100%)
Resistant 30 (60%)
Received treatment First-line hormone therapy 17 (34%) 50 (100%)
Docetaxel 21 (42%)
Cabazitaxel 3 (6%)
Enzalutamide 3 (6%)
Abiraterone 3 (6%)
[177Lu]Lu-PSMA-617 3 (6%)
Treatment group Antiandrogenic 23 (46%) 50 (100%)
Chemotherapeutic 24 (48%)
Radionuclide 3 (6%)